Nektar Therapeutics (NKTR) to Release Quarterly Earnings on Monday

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) is projected to post its quarterly earnings results before the market opens on Monday, March 3rd. Analysts expect Nektar Therapeutics to post earnings of ($0.18) per share and revenue of $36.65 million for the quarter.

Nektar Therapeutics Price Performance

NKTR traded up $0.02 during trading on Thursday, reaching $0.80. 1,307,413 shares of the company's stock were exchanged, compared to its average volume of 2,405,204. Nektar Therapeutics has a 1 year low of $0.65 and a 1 year high of $1.93. The company's fifty day simple moving average is $0.91 and its 200-day simple moving average is $1.11. The stock has a market capitalization of $146.87 million, a P/E ratio of -0.95 and a beta of 0.58.

Insider Activity

In related news, insider Jonathan Zalevsky sold 51,115 shares of the business's stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the sale, the insider now directly owns 326,904 shares in the company, valued at approximately $307,289.76. The trade was a 13.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Andrew Wilson sold 33,402 shares of the firm's stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.90, for a total value of $30,061.80. Following the completion of the transaction, the insider now owns 351,892 shares in the company, valued at $316,702.80. The trade was a 8.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 165,586 shares of company stock worth $159,990 in the last quarter. Corporate insiders own 3.71% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

NKTR has been the subject of a number of research reports. HC Wainwright restated a "buy" rating and set a $6.50 target price on shares of Nektar Therapeutics in a research report on Tuesday. William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a research note on Tuesday. Piper Sandler initiated coverage on Nektar Therapeutics in a research report on Monday, November 4th. They issued an "overweight" rating and a $7.00 price objective on the stock. Finally, B. Riley started coverage on shares of Nektar Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $4.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.08.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.